Business Context and Reporting Period
This Form 6-K filing by SciSparc Ltd. covers the month of September 2025. The report primarily discloses a corporate development event rather than routine financial results. On September 29, 2025, the Company announced that shareholders of N2OFF approved a merger with MitoCareX, a majority-owned subsidiary of SciSparc focused on drug discovery for resistant cancers, including pancreatic and non-small cell lung cancer.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a vehicle to incorporate a press release regarding a corporate transaction and does not contain a financial statement or earnings summary.
Material Changes
The material change disclosed is the shareholder approval of the merger between N2OFF and MitoCareX. This transaction consolidates the Company's drug discovery efforts within its majority-owned subsidiary structure. No financial performance changes versus prior periods are detailed in this document.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the merger approval. The filing does not contain specific financial guidance, forward-looking revenue projections, or a detailed discussion of risks and contingencies beyond the context of the merger itself. The press release incorporated by reference (Exhibit 99.1) contains the full details of the transaction.
Investor Verification Checklist
- Verify the terms and closing conditions of the N2OFF and MitoCareX merger in the full press release (Exhibit 99.1).
- Confirm the post-merger capital structure and ownership percentage of MitoCareX held by SciSparc.
- Review subsequent filings for the impact of this merger on the Company's consolidated financial statements.
- Check for any regulatory approvals required for the merger beyond the shareholder vote.